This is an automatically translated article.
Janumet is a drug to control blood sugar in patients with type 2 diabetes. The box contains 4 blisters x 7 tablets, which are made in the form of film-coated tablets. Patients need to strictly follow the indications and doses of Janumet to achieve effective treatment and avoid unwanted side effects.
1. Ingredients Janumet 50mg/500mg
Janumet includes the main ingredient is 64.25mg Sitagliptin Phosphate and Metformin Hydrochloride corresponding to:
50mg Sitagliptin free base; 500mg Metformin Hydrochloride; Sufficient excipient composition.
2. Indications and contraindications to the drug Janumet 50mg/500mg
Janumet 50mg / 500mg is indicated in the following cases:
Treatment of type 2 diabetes in patients taking Sitagliptin or Metformin monotherapy; Combined with Sulfonylurea to control type 2 diabetes as a supportive therapy with diet and physical exercise in the course of using any 2 drugs, Sitagliptin, Metformin, Sulfonylurea; In combination with Thiazolidione group of drugs to control type 2 diabetes as a supportive therapy in diet and physical activity in the course of 2 drugs of any 3 drugs: Sitagliptin, Metformin, Thiazolidinones; In combination with insulin in glycemic control with diet and physical activity in patients with type 2 diabetes. Janumet 50mg / 500mg should not be used in the following cases:
Patients with a history of hypersensitivity to the drug. Sitagliptin, Metformin or any of the ingredients; Renal disease or renal dysfunction as suggested by serum creatinine ≥1.5 mg/dL or abnormal creatinine clearance due to pathology such as cardiovascular collapse, acute myocardial infarction, and sepsis. Diabetic ketoacidosis.
3. Dosage and how to use Janumet 50mg/500mg
Usage:
Janumet 50mg/500mg is used orally. Patients should take Janumet tablets whole, do not chew, break, or crush as this can reduce the effectiveness of the drug. The drug is used at the same time with meals twice a day, morning and evening. The dose of Janumet should be individualized based on efficacy, tolerability and the patient's current treatment regimen, but the maximum recommended daily dose must be ensured. Dosage for specific cases:
Patients not controlled by Metformin monotherapy: the starting dose provides Sitagliptin 50mg/time, 2 times a day, taken with the current dose of Metformin. Patients not controlled with Sitagliptin monotherapy: The usual starting dose is 50mg Sitagliptin/500mg Metformin, twice daily. The dose may be increased to 50mg Sitagliptin/100mg Metformin, twice daily. The use of Janumet should not be switched to in patients with renal impairment receiving dose-adjusted sitagliptin. For patients currently taking Sitagliptin and Metformin in combination: Janumet can be started with the current dose of Sitagliptin and Metformin. For patients who do not have good blood sugar control when taking any 2 of the 3 drugs Sitagliptin, Metformin, and Sulfonylurea in combination: The initial dose of Sitagliptin is usually 50 mg/time, 2 times a day. The current dose of Metformin should be considered to determine the starting dose of the Metformin component. The dose of Metformin should be increased gradually to reduce the effect on the gastrointestinal tract. The dose of Sulfonylurea may be reduced in patients receiving or starting to take a Sulfonylurea. For patients who do not have good blood sugar control when taking any 2 of the 3 drugs Sitagliptin, Metformin, and Thiazolidinediones in combination: Initially, a dose of Sitagliptin is usually 50 mg/time, 2 times a day. The current dose of Metformin should be reviewed to determine the starting dose of the Metformin component and increased gradually to reduce adverse events. For patients who do not have good blood sugar control when taking any 2 of the 3 drugs Sitagliptin, Metformin, and Insulin in combination: Initially, Sitagliptin is usually 50mg/time, twice a day. The current dose of Metformin should be reviewed to determine the starting dose of the Metformin component and increased gradually to reduce adverse events. The dose of insulin may be reduced in patients taking or starting insulin.
4. Side effects of Janumet 50mg/500mg
Some unwanted side effects patients may experience when using Janumet:
Common side effects when combining Sitagliptin with Metformin are: Diarrhea, vomiting, flatulence, indigestion, headache, infection urinary tract. Common side effects when combining Sitagliptin with Sulfonylurea and Metformin are: Headache, hypoglycemia. Common side effects when combining Sitagliptin with insulin and Metformin are: Headache, low blood sugar.
5. Overdose of Janumet 50mg/500mg
There is no experience with doses of Sitagliptin above 800 mg/day in humans. In studies, no clinical adverse reactions were observed when doses of sitagliptin were greater than 600 mg/day for 10 days or 400 mg/day for 28 days. Metformin overdose occurs when using doses higher than 50g, symptoms may include lactic acidosis or hypoglycemia. When an overdose occurs, the patient should immediately stop taking the drug and go to a medical facility for proper treatment. Supportive measures such as removal of unabsorbed substances from the gastrointestinal tract, supportive treatment will be performed. Hemodialysis is a procedure that may be helpful in removing accumulated overdose from the blood.
6. Interactions of Janumet 50mg/500mg
Janumet may interact if used concurrently with the following drugs and substances:
Furosemide . Nifedipine. The cationic drugs excreted by the renal tubules: Amiloride, Digoxin, Morphine, Trimethoprim, Vancomycin.
7. Note when using Janumet 50mg/500mg
Do not use Janumet 50mg/500mg to treat patients with type 1 diabetes or diabetic ketoacidosis. Janumet medicine 50mg/500mg is not used for patients with liver failure and is contraindicated for people with kidney failure. Before starting treatment with Janumet, it is necessary to check kidney function and it is necessary to check regularly during the use of the drug. Metformin in Janumet may decrease vitamin B12 levels. It is necessary to increase vitamin B12 supplementation and check blood indicators annually when using Janumet. In case of suspected pancreatitis as a side effect of sitagliptin, the drug should be discontinued immediately. Withhold the drug in patients requiring radiographs containing oral contrast. Do not use alcohol, stimulants during treatment with Janumet. Care should be taken when administering Janumet to pregnant and lactating women. There are no reports of the effects of Janumet on the ability to drive and use machines. Above is the complete information about the drug Janumet. Patients need to carefully read the instructions for use, adhere to the correct dosage and important notes to bring the best treatment effect.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
